Alexander C Evans

6PUBLICATIONS
62CO-AUTHORS
Haematological tumoursPredictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jan 16, 2026
Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy.

Alberto G Conti, Alexander C Evans, Teresa von Linde

|Mar 05, 2025
Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity.

Jie Yang, Yumi Yamashita-Kanemaru, Benjamin I Morris

|Feb 10, 2025
Gut microbiota-derived hexa-acylated lipopolysaccharides enhance cancer immunotherapy responses.

Puspendu Sardar, Benjamin S Beresford-Jones, Wangmingyu Xia

|Jul 12, 2024
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy.

Charlotte J Imianowski, Paula Kuo, Sarah K Whiteside

|Dec 15, 2023
Acquisition of suppressive function by conventional T cells limits antitumor immunity upon Treg depletion.

Sarah K Whiteside, Francis M Grant, Giorgia Alvisi

|Sep 30, 2022
BACH2 restricts NK cell maturation and function, limiting immunity to cancer metastasis.

Charlotte J Imianowski, Sarah K Whiteside, Teresa Lozano

Pageof 1